Brief: Shanghai Junshi Biosciences Announces Approval Of Supplemental NDA For Ongericimab Injection By NMPA
27/05/2025 14:09
May 27 (Reuters) - Shanghai Junshi Biosciences Co Ltd 688180.SS: APPROVAL OF SUPPLEMENTAL NEW DRUG APPLICATION FOR ONGERICIMAB INJECTION BY NMPA Further company coverage: 688180.SS ((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Shanghai Junshi Biosciences
See all newsBrief: Shanghai Junshi Biosciences Q3 Net Loss At 170.9 Million Yuan
Brief: Shanghai Junshi Biosciences Q3 Net Loss At 170.9 Million Yuan
Brief: Shanghai Junshi Biosciences Receives Supplemental Drug Approval From NMPA
Brief: Shanghai Junshi Biosciences's Shareholder Plans To Cut Stake
Brief: Shanghai Junshi Biosciences Gets NMPA Acceptance Notice Of Supplemental Application For Toripalimab